Eur J Cancer: Paclitaxel is significantly better than docetaxel in fluoropyrimidine and platinum refractory esophageal squamous cell carcinoma!

Esophageal cancer is the sixth leading cause of cancer-related deaths in the world, and the incidence of esophageal cancer is rising rapidly in recent years
.

Esophageal squamous cell carcinoma (ESCC) is still the most common type of esophageal cancer in the world

Currently, there is no standard chemotherapy regimen for esophageal squamous cell carcinoma refractory to first-line fluoropyrimidine and platinum chemotherapy
.

This study is a randomized, selected phase II trial designed to compare the efficacy of docetaxel (DTX) and paclitaxel (PTX) in the treatment of such patients

Eligible patients were randomly divided into two groups and received DTX (70 mg/m ² , the first day of every 21-day course) or PTX (100 mg/m ² , every 49-day course of the first 1/8/15/22 /29 and 36 days) treatment
.

The primary endpoint is overall survival (OS), and secondary endpoints include progression-free survival (PFS), time to treatment failure (TTF), response rate (RR), and safety

^{2 2}

OS of two groups

OS of two groups

78 eligible patients (39 in each group) were included in the efficacy analysis
.

The OS of the PTX group was significantly longer than that of the DTX group (median OS: 8.

OS in the PTX group was significantly longer than that in the DTX group (median OS: 8.

PFS and TTF of the two groups

PFS and TTF of the two groups

The PFS and TTF of the PTX group were also significantly better than those of the DTX group (PFS: 4.
4 vs 2.
1, HR 0.
49, p=0.
002; TTF: 3.
8 vs 2.
1, HR 0.
45, p<0.
001)
.

The RR of the PTX group was also higher than that of the DTX group (25.

The PFS and TTF of the PTX group were also significantly better than the DTX group (PFS: 4.

Various objective response rates

Various objective response rates

Compared with the PTX group, the DTX group had grade 3 and above neutropenia (28% vs 80%), leukopenia (28% vs 76%), and febrile neutropenia (0% vs 46 %; p<0.
0001) The incidence was significantly higher
.

Compared with the PTX group, the DTX group had grade 3 and above neutropenia (28% vs 80%), leukopenia (28% vs 76%), and febrile neutropenia (0% vs 46 %; p<0.
0001) The incidence was significantly higher
.

In summary, among patients with esophageal squamous cell carcinoma refractory to first-line fluoropyrimidine and platinum-based chemotherapy, PTX shows significantly better efficacy and more controllable safety compared with DTX
.

In patients with esophageal squamous cell carcinoma refractory to first-line fluoropyrimidine and platinum-based chemotherapy, compared with DTX, PTX showed significantly better efficacy and more controllable safety
.

In patients with esophageal squamous cell carcinoma refractory to first-line fluoropyrimidine and platinum chemotherapy, PTX showed significantly better efficacy and more controllable safety compared with DTX

Original source:

Yamamoto Sachiko,Kawakami Hisato,Kii Takayuki et al.

Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201 in this message